Use of clinical apps significantly improves quality of cardiovascular care

February 14, 2019

A pilot program using several clinical decision support tools in the outpatient setting to treat and educate stable ischemic heart disease patients has shown success in improving angina in these patients. Findings from the Florida Cardiovascular Quality Network study were presented at the American College of Cardiology's Cardiovascular Summit in Orlando. The conference brings together top experts to discuss and review innovative, relevant cardiovascular management and leadership strategies.

Stable ischemic heart disease (SIHD) is a form of coronary heart disease that causes recurring chest pain or discomfort--known as angina--when part of the heart does not receive enough blood. According to the researchers these patients typically have a complex medical presentation that requires the clinician to address a number of clinical factors. In stable angina patients, optimal cardiology care is achieved through compliance with SIHD guideline recommendations, including assessment of CV risk factors, quantitative scoring of angina symptomatology, documentation of appropriate use criteria (AUC) for diagnostic testing, as well as success rates in efforts to decrease CV risk factors.

"Clinical support tools--or apps--are becoming an integral part of routine clinical procedure," said lead study author A. Allen Seals, MD, FACC, a cardiologist with St. Vincent's Healthcare in Jacksonville, Florida. "These tools do not promote 'cookbook medicine' but quite the opposite. They assist the provider in individualizing the care of each patient to follow national cardiovascular care guidelines."

Using data from the Florida Cardiovascular Quality Network, researchers analyzed 254 patients who all had angina symptoms and presented for clinical evaluation. There were 188 patients in group A, in which all patients did not have pre-existing SIHD, and 66 patients in group B, in which all patients did have pre-existing SIHD. The overall patient population was 53 percent female and 47 percent male and had an average age of 64 years.

Use of Apps in the Clinic Setting

Three apps were used in the study: ACC FOCUS as a clinical decision support app for imaging AUC documentation, Seattle Angina Questionnaire app to determine symptom severity and quality of life, and the CardioSmart Heart Explorer App to educate patients.

The apps were provided to the care teams in tablet format after determining other mobile devices and/or laptop hardware were either too small or too big for ease of use in the clinic setting. The tablet was shared by the team, and each patient's data was securely entered. The data output from each app was available and shared as routine clinical information available on each patient. This protocol was repeated at each patient visit: baseline, 3 months, 6 months and 12 months. The specific apps chosen were consistent with the underlying SIHD diagnosis.

"The ACC and other stakeholders publish guidelines that represent comprehensive clinical documents that have established the standard for optimal cardiovascular care," Seals said. "Clinical decision support tools [apps] effectively translate these guidelines into a format that assists the provider with the integration of guideline-based diagnostic and treatment recommendations into clinical practice."

RESULTS

ACC FOCUS

The ACC FOCUS app was developed for use in the clinic and collected patient-specific information and applied software-based AUC to assist in determining the most appropriate functional study (stress test) for the individual patient. FOCUS has since been discontinued. Instead, the algorithms used are now available for licensing to clinical decision support mechanism (CDSM) vendors in order to provide institutions with more choices in how to meet the approaching federal AUC mandate start date on Jan. 1, 2020.

Clinic sites in the study used FOCUS for imaging AUC documentation. Researchers found imaging AUC was appropriate 91 percent of the time, possibly appropriate 8 percent of the time and rarely appropriate 0.8 percent of the time.

Seattle Angina Questionnaire

The Seattle Angina Questionnaire is recognized as the most reliable, most reproducible and most clinically useful quantitative measurement of angina symptomatology and is the most commonly utilized clinical decision support tool for the determination of symptoms in SIHD patients. It utilizes a series of questions that are then reported on a five score system: summary score, angina severity, angina frequency, quality of life and physical limitation. All five Seattle Angina Questionnaire scores are quantified on a scale of 0-100 with 100 equivalent to an asymptomatic or highest quality of life score.

For the purposes of the study, a proprietary app was developed that presented the Seattle Angina Questionnaire in an electronic format that was easy for patient understanding and was readily adopted. At the baseline visit and the 12-month visit, patients' average Seattle Angina Questionnaire scores were as follows:CardioSmart Heart Explorer

The ACC's CardioSmart Heart Explorer app is a highly interactive software designed as both a patient risk factor modification tool, as well as a resource for physicians and cardiac care team professionals. It is organized by heart conditions, heart drugs, heart treatments, heart basics and healthy living. The healthy living tab has a large amount of basic and advanced information in a user-friendly format designed to enhance patient education, promote patient compliance and ultimately improve a patient's risk factor profile. The researchers also helped patients use the main CardioSmart website: CardioSmart.org.

Researchers found the CardioSmart Heart Explorer app assisted in effective risk factor medication in 81 percent of patients.

Apps in Practice and Going Forward

"Importantly, the utilization of multiple apps proved to be clinically feasible and did not overly impair efficiency of the team-based providers," Seals said. "In a team-based environment, patients should welcome the utilization of apps at the point of care and have confidence that these apps will have excellent value to their provider to improve the quality of cardiovascular care."

According to the Florida researchers, other key questions that need to be answered include whether structured use of apps at the point of care can be proven to impact quality of care in a larger patient population as well as in other disease states such as high cholesterol or atrial fibrillation. Also, it remains to be demonstrated that a systematic utilization of clinical decision support apps will positively impact long term outcomes such as decreasing hospitalizations and lowering mortality.

The Florida Cardiovascular Quality Network plans to expand the number of clinical sites and the number of team-based providers supported by this innovative method of bringing American College of Cardiology guidelines and clinical decision support tools to the point of patient care.
-end-
The American College of Cardiology envisions a world where innovation and knowledge optimize cardiovascular care and outcomes. As the professional home for the entire cardiovascular care team, the mission of the College and its more than 52,000 members is to transform cardiovascular care and to improve heart health. The ACC bestows credentials upon cardiovascular professionals who meet stringent qualifications and leads in the formation of health policy, standards and guidelines. The College also provides professional medical education, disseminates cardiovascular research through its world-renowned JACC Journals, operates national registries to measure and improve care, and offers cardiovascular accreditation to hospitals and institutions. For more, visit acc.org.

American College of Cardiology

Related Angina Articles from Brightsurf:

Angina drug fails to improve outcomes after successful revascularisation
Trimetazidine administered after successful percutaneous coronary intervention (PCI) does not improve outcomes in patients with chronic or acute coronary syndromes, according to results of the ATPCI trial presented in a Hot Line session today at ESC Congress 2020.

Nutritional screening a potential tool for determining heart attack, angina prognosis
In a study published today in the Journal of the American College of Cardiology of more than 5,000 acute coronary syndromes (ACS) patients, 71.8% were considered malnourished by at least one nutrition screening test, and worsening malnutrition status was associated with higher mortality and major adverse cardiovascular events (MACE), such as another heart attack or stroke.

Cell therapy treatment for cardiac patients with microvascular dysfunction provides enhanced quality
Trial results presented today revealed a promising therapy for patients experiencing angina due to coronary microvascular dysfunction (CMD).

Clinical trial in China on acupuncture as added treatment for chronic stable angina
This randomized clinical trial with about 400 adults conducted in China investigated acupuncture as an added treatment to antianginal therapies in reducing the frequency of angina attacks in patients with chronic stable angina.

Simple scan could direct treatments for angina
A 40 minute test for angina could help patients avoid an overnight stay in hospital, according to research funded by the NIHR Guy's and St Thomas' Biomedical Research Centre.

Cognitive decline may accelerate after heart attack, angina
Adults with incident coronary heart disease (CHD) are at higher risk for faster cognitive decline in the long-term, according to a study published today in the Journal of the American College of Cardiology.

Epidemiology, pathophysiology, and therapeutic targets in stable ischemic heart disease
In the current issue of Cardiovascular Innovations and Applications, C.

Henry Ford Hospital patient is first in the US to receive angina device
Cardiologists at Henry Ford Hospital performed the first implantation in the United States of a device approved for use in Europe for hard-to-treat angina.

Statins may bring benefits at time of treatment for heart attack, angina
Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broad population of patients slated to undergo percutaneous coronary intervention (PCI), a procedure to clear blocked arteries, in a trial being presented at the American College of Cardiology's 67th Annual Scientific Session.

Study of heart stents for stable angina highlights potential of placebo effect
Researchers at Imperial College London have explored the placebo effects of a coronary angioplasty procedure with stents for the first time.

Read More: Angina News and Angina Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.